Journal of Renal Nutrition
Volume 20, Issue 3 , Pages 141-150 , May 2010

Roles of Calcium-Sensing Receptor and Vitamin D Receptor in the Pathophysiology of Secondary Hyperparathyroidism

  • Linda M. McCann, RD, LD, CSR

      Affiliations

    • Dialysis Division, Satellite Healthcare, Mountain View, California
    • Corresponding Author InformationAddress reprint requests to Linda M. McCann, RD, LD, CSR, Dialysis Division, Satellite Healthcare, 401 Castro St., Mountain View, CA 94041.
    • ,
  • Judith Beto, PhD, RD, FADA

      Affiliations

    • Division of Nephrology and Hypertension, Loyola University Medical Center, Maywood, Illinois

References 

  1. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187
  2. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: A key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Ren Physiol. 2005;288:F253–F264
  3. Martinez I, Saracho R, Montenegro J, et al. The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496–502
  4. Owda A, Elhwairis H, Narra S, et al. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail. 2003;25:595–602
  5. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am J Kidney Dis. 1997;29:862–865
  6. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000;35:1226–1237
  7. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  8. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  9. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001;81:239–297
  10. Brown EM, Pollak M, Hebert SC. Cloning and characterization of extracellular Ca2+-sensing receptors from parathyroid and kidney: Molecular physiology and pathophysiology of Ca2+-sensing. Endocrinologist. 1994;4:419–426
  11. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol. 2008;23:1203–1210
  12. Mundy GR, Guise TA. Hormonal control of calcium homeostasis. Clin Chem. 1999;45:1347–1352
  13. Talmage RV, VanderWiel CJ, Matthews JL. Calcitonin and phosphate. Mol Cell Endocrinol. 1981;24:235–251
  14. Scherubl H, Kleppisch T, Zink A, et al. Major role of dihydropyridine-sensitive Ca2+ channels in Ca2+-induced calcitonin secretion. Am J Physiol. 1993;264:E354–E360
  15. Ikegame M, Ejiri S, Ozawa H. Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors. Bone. 2004;35:27–33
  16. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Ren Physiol. 2005;289:F8–F28
  17. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature. 1993;366:575–580
  18. Kifor O, Diaz R, Butters R, et al. The calcium-sensing receptor is localized in caveolin-rich plasma membrane domains of bovine parathyroid cells. J Biol Chem. 1998;273:21708–21713
  19. Thiele J. The human parathyroid chief cell—A model for a polypeptide hormone producing endocrine unit as revealed by various functional and pathological conditions. A thin section and freeze-fracture study. J Submicrosc Cytol. 1986;18:205–220
  20. Garrett JE, Capuano IV, Hammerland LG, et al. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem. 1995;270:12919–12925
  21. Huang Y, Zhou Y, Yang W, et al. Identification and dissection of Ca2+-binding sites in the extracellular domain of Ca2+-sensing receptor. J Biol Chem. 2007;282:19000–19010
  22. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord. 2000;1:307–315
  23. LeBoff MS, Shoback D, Brown EM, et al. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest. 1985;75:49–57
  24. Brent GA, LeBoff MS, Seely EW, et al. Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans. J Clin Endocrinol Metab. 1988;67:944–950
  25. Moallem E, Kilav R, Silver J, et al. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem. 1998;273:5253–5259
  26. Brauner-Osborne H, Jensen AA, Sheppard PO, et al. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain. J Biol Chem. 1999;274:18382–18386
  27. National Kidney Foundation. K/DOQI practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1–S201
  28. Naveh-Many T, Bell O, Silver J, et al. Cis and trans acting factors in the regulation of parathyroid hormone (PTH) mRNA stability by calcium and phosphate. FEBS Lett. 2002;529:60–64
  29. Levi R, Ben-Dov IZ, Lavi-Moshayoff V, et al. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: Correlation with posttranslational modification of the trans acting factor AUF1. J Am Soc Nephrol. 2006;17:107–112
  30. Okada Y, Montero A, Zhang X, et al. Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. J Biol Chem. 2003;278:21258–21266
  31. McSheehy PM, Chambers TJ. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology. 1986;118:824–828
  32. Messer HH, Yuen SY, Copp DH. Net uptake and release of calcium and phosphate by bone in vitro: Effects of medium calcium and phosphate concentrations. Calcif Tissue Res. 1975;19:1–7
  33. Fu Q, Jilka RL, Manolagas SC, et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 2002;277:48868–48875
  34. Hofbauer LC, Kuhne CA, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuron Interact. 2004;4:268–275
  35. Udagawa N, Takahashi N, Jimi E, et al. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor. Bone. 1999;25:517–523
  36. Bindels RJ. Calcium handling by the mammalian kidney. J Exp Biol. 1993;184:89–104
  37. Murer H, Hernando N, Forster I, et al. Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiol Rev. 2000;80:1373–1409
  38. Healy KD, Vanhooke JL, Prahl JM, et al. Parathyroid hormone decreases renal vitamin D receptor expression in vivo. Proc Natl Acad Sci USA. 2005;102:4724–4728
  39. Kong XF, Zhu XH, Pei YL, et al. Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D3-1α-hydroxylase gene. Proc Natl Acad Sci USA. 1999;96:6988–6993
  40. Riccardi D, Park J, Lee WS, et al. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA. 1995;92:131–135
  41. Chang W, Tu C, Chen TH, et al. Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology. 1999;140:5883–5893
  42. Gama L, Baxendale-Cox LM, Breitwieser GE. Ca2+-sensing receptors in intestinal epithelium. Am J Physiol. 1997;273:C1168–C1175
  43. Riccardi D, Lee WS, Lee K, et al. Localization of the extracellular Ca2+-sensing receptor and PTH/PTHrP receptor in rat kidney. Am J Physiol. 1996;271:F951–F956
  44. Houillier P, Paillard M. Calcium-sensing receptor and renal cation handling. Nephrol Dial Transplant. 2003;18:2467–2470
  45. Motoyama HI, Friedman PA. Calcium-sensing receptor regulation of PTH-dependent calcium absorption by mouse cortical ascending limbs. Am J Physiol Ren Physiol. 2002;283:F399–F406
  46. Hendy GN, D'Souza-Li L, Yang B, et al. Mutations of the calcium-sensing receptor (CASR) in familial hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2000;16:281–296
  47. Attie MF, Gill JR, Stock JL, et al. Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. J Clin Invest. 1983;72:667–676
  48. Kos CH, Karaplis AC, Peng JB, et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest. 2003;111:1021–1028
  49. Dvorak MM, Chen TH, Orwoll B, et al. Constitutive activity of the osteoblast Ca2+-sensing receptor promotes loss of cancellous bone. Endocrinology. 2007;148:3156–3163
  50. Kirchhoff P, Geibel JP. Role of calcium and other trace elements in the gastrointestinal physiology. World J Gastroenterol. 2006;12:3229–3236
  51. Cheng SX, Okuda M, Hall AE, et al. Expression of calcium-sensing receptor in rat colonic epithelium: Evidence for modulation of fluid secretion. Am J Physiol Gastrointest Liver Physiol. 2002;283:G240–G250
  52. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: A historical perspective. Pediatrics. 2003;112:e132–e135
  53. DeLuca HF. The vitamin D story: A collaborative effort of basic science and clinical medicine. FASEB J. 1988;2:224–236
  54. Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?. Kidney Int. 1999;55:2169–2177
  55. Saab G, Young DO, Gincherman Y, et al. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007;105:c132–c138
  56. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the Study to Evaluate Early Kidney Disease. Kidney Int. 2007;71:31–38
  57. Chonchol M, Scragg R. 25-hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007;71:134–139
  58. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013
  59. Mirams M, Robinson BG, Mason RS, et al. Bone as a source of FGF23: Regulation by phosphate?. Bone. 2004;35:1192–1199
  60. Yoshiko Y, Wang H, Minamizaki T, et al. Mineralized tissue cells are a principal source of FGF23. Bone. 2007;40:1565–1573
  61. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–568
  62. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23:1509–1518
  63. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435
  64. Urena Torres P, Friedlander G, de Vernejoul MC, et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int. 2008;73:102–107
  65. Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA. 1988;85:3294–3298
  66. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol. 1999;277:F157–FF175
  67. Vaisanen S, Juntunen K, Itkonen A, et al. Conformational studies of human vitamin-D receptor by antipeptide antibodies, partial proteolytic digestion and ligand binding. Eur J Biochem. 1997;248:156–162
  68. Cheng JB, Motola DL, Mangelsdorf DJ, et al. De-orphanization of cytochrome P450 2R1: A microsomal vitamin D 25-hydroxylase. J Biol Chem. 2003;278:38084–38093
  69. Masumoto O, Ohyama Y, Okuda K. Purification and characterization of vitamin D 25-hydroxylase from rat liver mitochondria. J Biol Chem. 1988;263:14256–14260
  70. Fraser DR, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970;228:764–766
  71. Kawashima H, Torikai S, Kurokawa K. Localization of 25-hydroxyvitamin D3 1α-hydroxylase and 24-hydroxylase along the rat nephron. Proc Natl Acad Sci USA. 1981;78:1199–1203
  72. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–894
  73. Bikle D. Extra renal synthesis of 1,25-dihydroxyvitamin D and its health implications. Clin Rev Bone Miner Metab. 2009;7:114–125
  74. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662–687
  75. Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology. 1998;139:4391–4396
  76. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, et al. Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc Natl Acad Sci USA. 2001;98:13324–13329
  77. Segawa H, Kaneko I, Yamanaka S, et al. Intestinal Na-Pi cotransporter adaptation to dietary Pi content in vitamin D receptor null mice. Am J Physiol Ren Physiol. 2004;287:F39–F47
  78. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1α-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279:16754–16766
  79. Silver J, Naveh-Many T, Mayer H, et al. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest. 1986;78:1296–1301
  80. Brown AJ, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol. 1996;270:F454–F460
  81. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem. 2002;277:30337–30350
  82. Takeyama K, Kitanaka S, Sato T, et al. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science. 1997;277:1827–1830
  83. Brenza HL, Kimmel-Jehan C, Jehan F, et al. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA. 1998;95:1387–1391
  84. Bland R, Zehnder D, Hughes SV, et al. Regulation of vitamin D-1alpha-hydroxylase in a human cortical collecting duct cell line. Kidney Int. 2001;60:1277–1286
  85. Beckman MJ, DeLuca HF. Regulation of renal vitamin D receptor is an important determinant of 1alpha,25-dihydroxyvitamin D(3) levels in vivo. Arch Biochem Biophys. 2002;401:44–52
  86. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59:1187–1201
  87. Bover J, Jara A, Trinidad P, et al. Dynamics of skeletal resistance to parathyroid hormone in the rat: Effect of renal failure and dietary phosphorus. Bone. 1999;25:279–285
  88. Portale AA, Halloran BP, Morris RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83:1494–1499
  89. Bricker NS. On the pathogenesis of the uremic state. An exposition of the “trade-off hypothesis”. N Engl J Med. 1972;286:1093–1099
  90. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:34–38
  91. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47:1434–1442
  92. Kilav R, Silver J, Biber J, et al. Coordinate regulation of rat renal parathyroid hormone receptor mRNA and Na-Pi cotransporter mRNA and protein. Am J Physiol. 1995;268:F1017–F1022
  93. Naveh-Many T, Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest. 1990;86:1313–1319
  94. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996;97:2534–2540
  95. Tominaga Y. Mechanism of parathyroid tumourigenesis in uraemia. Nephrol Dial Transplant. 1999;14:63–65
  96. Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol. 2000;11:1141–1152
  97. Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328–336
  98. Yano S, Sugimoto T, Tsukamoto T, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980–1986
  99. Canadillas S, Canalejo A, Santamaria R, et al. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol. 2005;16:2190–2197
  100. Mizobuchi M, Hatamura I, Ogata H, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579–2587
  101. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67:467–476
  102. Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436–1443
  103. Kremer R, Bolivar I, Goltzman D, et al. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology. 1989;125:935–941
  104. Tokumoto M, Taniguchi M, Matsuo D, et al. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: Vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther Apher Dial. 2005;9(Suppl):S27–S34
  105. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  106. Drueke TB, Touam M, Thornley-Brown D, et al. Extraskeletal calcification in patients with chronic kidney failure. Adv Nephrol Necker Hosp. 2000;30:333–356
  107. Danese MD, Kim J, Doan QV, et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149–156
  108. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73:1296–1302
  109. Guerin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014–1021
  110. Raggi P. Cardiovascular calcification in end stage renal disease. Contrib Nephrol. 2005;149:272–278
  111. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–942
  112. De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13:2762–2769
  113. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–2138
  114. Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2005;17:262–270
  115. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002;17:2094–2105
  116. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  117. Weisinger JR, Favus MJ, Langman CB, et al. Regulation of 1,25-dihydroxyvitamin D3 by calcium in the parathyroidectomized, parathyroid hormone-replete rat. J Bone Miner Res. 1989;4:929–935

PII: S1051-2276(10)00005-1

doi: 10.1053/j.jrn.2010.01.004

Journal of Renal Nutrition
Volume 20, Issue 3 , Pages 141-150 , May 2010

Article Tools

* Image Usage & Resolution